Tanycytes, Tau, and the Hidden Brain–Blood Bridge (Why Clearance Matters More Than You Think)

This is how a tiny bridge in your brain’s “floor” quietly shuttles Tau and shapes Alzheimer’s disease.

Image created by the author

Alzheimer’s disease is characterized by pathological Tau protein accumulation in the brain and cerebrospinal fluid instead of timely efflux into the blood.

If you want a quick visual summary before we get into the science, this short video shows how Tau moves from cerebrospinal fluid to blood through tanycytes in the median eminence.

[embed]

Clearing Tau when brain cleanup fails

Alzheimer’s disease and other age-related cognitive disorders have become a major public health concern in aging societies. Under these conditions, proteins such as amyloid-beta and Tau build up in the brain as plaques and tangles, which are linked to neuronal dysfunction and death.

Under normal conditions, these proteins are released from cells and cleared from the brain, either by degradation or by transport out of the brain.

But this system can go wrong.

Tau levels increase in the cerebrospinal fluid (CSF), where Tau is present in soluble forms with changes such as phosphorylation and truncation. The CSF seems to act as a stepping stone in a multistep clearance pathway, in which Tau is moved from brain tissue into the CSF and then further cleared, possibly through the glymphatic system, before leaving the CSF.

We know that CSF-borne Tau can reach the bloodstream, and that circulating Tau is even considered a potential biomarker for disease. However, the known pathways for moving Tau from CSF to blood do not thoroughly match the relatively rapid kinetics with which Tau can disappear from the CSF.

This mismatch strongly suggests alternative clearance routes that are not completely understood.

Tanycytes — the new player

A recent focus has turned to special ependymoglial cells called tanycytes that line the walls and floor of the third ventricle. These cells lie in hypothalamic regions near the third ventricle and have been highlighted as hotspots for age-related changes in gene expression.

The brain-to-blood transfer of molecules is usually thought of in terms of two main barriers. One is the classic blood–brain barrier, formed by the endothelium of brain blood vessels. The other is the blood-CSF barrier, located at the choroid plexus and certain circumventricular organs, including the median eminence of the hypothalamus.

The median eminence is rich in highly permeable fenestrated blood vessels and forms part of the pituitary portal vasculature. This specialized vasculature allows signals from the body to reach the brain and brain products and neurohormones to reach the pituitary.

Tanycytes extend long, slim processes from their cell bodies at the ventricular wall to endfeet that contact these fenestrated capillaries. Because the fenestrated capillaries are leaky, tanycytes effectively take over the barrier function by forming tight junctions at the ventricular wall.

In this way, they connect the CSF and the pituitary portal circulation, controlling what passes between them. Rather than acting as passive barriers, they play an active role by moving blood-borne signals into the CSF as part of their gatekeeping function.

The big question is whether tanycytes could also operate in reverse, sending molecules from CSF toward the blood. This question led directly to an investigation of their role in Tau transport.

Tanycytes as Tau transporters

Researchers explored whether Tau could be transported by tanycytes using both cellular and in vivo models. In primary rat tanycyte cultures, they used a recombinant human 2N4R Tau isoform tagged with a fluorescent label, termed Tau-565. This Tau-565 preparation contained a mix of Tau molecules carrying one to five fluorophores to enable tracking of internalization.

After incubating primary rat tanycytes with Tau-565 for 30 minutes, Tau-positive vesicles formed inside the cells. These vesicles were observed by Tau-565 fluorescence and confirmed by Tau immunolabeling with a Tau-5 antibody.

In untreated tanycytes, Tau was not detected on the Western blot. Still, a 30-minute treatment with unconjugated human recombinant 2N4R Tau produced a clear signal, indicating that uptake was not an artifact of the fluorophore.

Finding clathrin-positive and EEA1-positive endosomes with Tau-565 pointed to clathrin-mediated endocytosis. Live-cell imaging with a membrane dye showed Tau-565-positive vesicles moving inside tanycytes, which suggests there is active transport and secretion.

The detection of SNARE proteins such as vesicle-associated membrane protein 1 (VAMP1) further suggested that Tau could be secreted via exocytosis.

To test secretion directly, primary rat tanycytes were incubated with Tau-565 for 30 minutes and then monitored over time using a human Tau-specific ELISA in fresh medium.

There was a rapid release of Tau into the medium that increased over time. This pattern supports the view that Tau uptake by tanycytes is the first step toward tanycytic clearance.

The pituitary route (from CSF to blood)

To move beyond cell culture, Tau transport was examined in wild-type mice in vivo. Tau-565 was injected into the lateral ventricle by intracerebroventricular injection. It was then tracked in the pituitary and general circulation with immunohistofluorescence and ELISA.

In the brain, Tau appeared at the luminal surface of the ventricular wall at all time points examined. Ventral tanycytes were positive for Tau as early as the end of the brief injection period, with Tau-565 filling their cell bodies and processes down to their endfeet.

This pattern matched observations in primary rat tanycytes and aligned with the idea that tanycytes trap Tau from the CSF. Interestingly, Tau accumulation in tanycytic cell bodies and processes was no longer visible an hour after injection, resembling its exocytosis over time.

Light-sheet imaging of cleared brains 30 minutes after injection showed Tau-565 spread throughout the ventricular system, but not in the brain parenchyma or choroid plexus. The signal was strongest along the median eminence, particularly in ventral tanycytes that form the floor of the third ventricle, highlighting their important role.

To ensure that the fluorescent label itself was not driving tanycytic transport, a control fluorophore-coupled protein, BSA-565, was injected and stayed along the ventricular lumen without entering tanycytic bodies or endfeet.

Because the median eminence vasculature forms part of the pituitary portal system, Tau released by tanycytic endfeet would be expected to follow a pituitary route. Indeed, pituitaries from Tau-565-injected mice showed Tau-565 fluorescence 30 minutes post-injection.

ELISA measurements detected recombinant human Tau in pituitary tissue as early as 15 minutes after injection and up to 1 hour later. In peripheral blood serum, Tau appeared at 30 minutes after injection and then decreased by the second hour.

Serial tail-blood sampling showed Tau kinetics similar to those seen with terminal blood collection, with no major differences between sexes. Deep cervical lymph nodes also had higher Tau levels. Still, this increase occurred after the rise in the pituitary. Then it decreased, following the same pattern as serum, rather than occurring first.

Overall, these results suggest that Tau may move from CSF to blood primarily via tanycytes and the pituitary portal system, whereas lymphatic pathways contribute more slowly.

First, tanycytes take up Tau from the CSF, carry it through their structures, and then release it into the pituitary portal system at the median eminence. Next, Tau moves through the portal system to the anterior pituitary, then drains into the pituitary veins with portal blood, finally reaching the peripheral circulation.

What happens when tanycytes fail (blocking the bridge)

To test how crucial tanycytic vesicular transport is, a model was created in which vesicular transport was disrupted specifically in these cells. This was done using a floxed BoNTB transgene (iBot mice) selectively driven in tanycytes via AAV12-Dio2-iCre-GFP.

BoNTB cleaves VAMP1 and VAMP2, blocking exocytosis, and also targets VAMP3, which is involved in endocytosis, thereby affecting the entire transcytotic pathway.

Several factors ensured selectivity of transduction to tanycytes. The virus was injected into the ventricular system to avoid parenchymal transduction, and its tropism favored ependymal cells, including tanycytes.

Using the Dio2 promoter, which is enriched in tanycytes relative to other ependymal cells, further focused expression, resulting in approximately 71% ventral and 41% dorsal tanycyte transduction.

When Tau-565 was injected in these iBot mice, there was a marked reduction in Tau-565 signal in tanycytic processes, endfeet, and the underlying capillary bed. Uptake by many transduced tanycytic cell bodies at the ventricular wall also dropped substantially.

Functionally, blocking tanycytic vesicular transport blunted CSF-to-blood Tau efflux. Pituitary Tau was almost halved, and serum Tau was reduced about fourfold compared with wild-type mice, 30 minutes after injection.

In a tauopathy model (THY-Tau22 mice), combining this blockade (THY-Tau22 iBot) increased AT8-positive Tau pathology, particularly in the posterior hippocampus, and increased certain pathological Tau species, such as pS199 and pT181, in hippocampal extracts.

This link between disrupted tanycytic shuttling and worsening Tau pathology suggests that intact tanycytic function is protective.

Tanycytes in human disease

The observations in animal and cellular models were extended to the human context. In patients with Alzheimer’s disease, plasma-to-CSF ratios of total and p181 Tau were decreased, consistent with reduced Tau efflux from CSF to blood.

By contrast, ratios of other brain-derived proteins, such as neurofilament light chain and GFAP, were not reduced, suggesting a more specific Tau-clearance problem rather than a general barrier failure.

When researchers looked at postmortem brains from people with Alzheimer’s disease, they noticed clear changes in tanycytes. Rather than having long, unbroken projections, these cells had broken-up processes that looked like a string of pearls.

GFAP and GPR50 labeling confirmed that these changes were specific to tanycytes and not present in neighboring astrocytes.

This fragmentation disrupted tanycyte-capillary interactions, as shown by vimentin-labeled endfeet and Cav1-labeled capillary walls, implying functional consequences for Tau clearance and other blood-brain exchanges in which tanycytes play a major role.

Fragmentation was seen more often in areas close to the third ventricle, such as the infundibulum and the median eminence’s internal zone. It happened less often in the outer regions, which suggests a connection between CSF exposure and tanycytic pathology.

To see whether this was specific to Alzheimer’s, vimentin immunolabeling was compared in control subjects, Alzheimer’s disease patients, and patients with frontotemporal dementia (FTD) of either TDP-43 or Tau type.

Tanycytic processes in FTD patients were also morphologically distinct from those in controls. They had a lower process density, but, except for one FTD brain that also showed Alzheimer’s disease hallmarks, they did not display beading.

This suggests that while tanycytic pathology can occur in several neurodegenerative disorders, breakdown or beading of the tanycytic cytoskeleton is specific to Alzheimer’s disease and likely interferes with Tau efflux from the CSF.

Stress inside the tanycytes

To understand why tanycytes break down in Alzheimer’s, single-nucleus RNA sequencing (snRNAseq) of hypothalamic tissue from control and Alzheimer’s disease patients was performed.

The dataset contained tens of thousands of nuclei from various cell types, including three tanycytic subpopulations that all showed the expected canonical markers. One subtype, 2 tanycytes, was much less common in patients with Alzheimer’s disease, which matches the observed loss in the infundibulum.

Differentially expressed genes in tanycytes included stress-related factors such as HIF1A and HIF3A and their downstream targets VEGFA and ENO1, metallothionein genes, oxidative stress genes such as SOD2 and SESN1/2, and cell death-linked genes such as BNIP3, DDIT4, and CLU.

These changes hint at a significant activation of diverse cellular stress response pathways and the triggering of cell death mechanisms in tanycytes.

Gene Ontology analysis showed enrichment for terms related to vesicle docking in exocytosis, cellular response to hypoxia, reactive oxygen species, detoxification, stress response to metal ions, thyroid hormone metabolism, ion homeostasis, glucose and lipid metabolism, and bleb assembly.

Taken together, these results point to widespread problems with tanycytic function in Alzheimer’s disease that go well beyond the visible beading. They integrate structural breakdown, stress responses, and changes in vesicle transport into a single picture of poor Tau clearance.

What models can and cannot reveal

Four different animal models of Alzheimer’s disease (three mouse models and a mouse lemur model with intracerebral inoculation of Alzheimer’s disease brain extracts) were examined for tanycytic degradation.

None of these models showed the same tanycytic fragmentation observed in human Alzheimer’s disease, despite developing A and Tau pathologies and other Alzheimer’s disease-like hallmarks.

This indicates that the specific “string of pearls” tanycytic phenotype is, so far, a human feature in this work and highlights the limitations of current animal models in this regard.

Key insights and takeaways

The experiments show that primary tanycytes take up Tau-565 into vesicles and then release Tau into the medium over time. The ventral tanycytes in vivo fill with Tau-565 and later lose this signal as it appears in the pituitary and blood.

Any approach that keeps these basic steps of endocytosis, intracellular transport, and exocytosis intact in tanycytes directly supports Tau clearance from CSF to blood.

BoNTB-mediated cleavage of VAMP proteins in iBot mice reduces Tau-565 uptake in tanycytic bodies and processes, halves pituitary Tau. It lowers serum Tau roughly fourfold while worsening hippocampal Tau pathology.

These results underline that preserving vesicular transport machinery (clathrin, EEA1, VAMP-linked exocytosis) in tanycytes is central to maintaining their role as Tau shuttles.

The timing of Tau appearance in the pituitary and serum, along with reduced plasma-to-CSF Tau and pTau181 ratios in patients with Alzheimer’s disease, supports the idea that tanycyte-mediated transfer is a key step in clearance.

Signals and conditions that influence the median eminence, pituitary portal circulation, and tanycytic stress states, therefore, directly affect Tau efflux efficiency.

Anatomical and transcriptomic findings show fragmented processes, reduced process area, increased fragment area, and strong activation of hypoxia and oxidative stress pathways in Alzheimer’s disease tanycytes.

If we can prevent or reduce this degeneration and beading, it will help keep tanycytic processes continuous and maintain intact endfoot-capillary contacts. These are important for Tau to move effectively from CSF to blood.

Across in vitro, in vivo, and human data, the scientific studies have constructed a coherent picture of a brain-to-blood tanycytic shuttle for Tau that is impaired in Alzheimer’s disease.

Any intervention that maintains this shuttle’s structure and vesicular transport, or restores it when damaged, directly addresses the Tau clearance deficit and may limit Tau accumulation and its downstream pathological effects.

Why does this matter so much for brain health

The story of tanycytes and Tau shows that brain health is not only about how much Tau is produced, but also about how effectively it is cleared.

A specialized bridge between CSF and blood, formed by tanycytes at the median eminence, can determine whether Tau is removed or allowed to build up. When this bridge functions well, Tau can be taken up, transported, and efficiently released into the pituitary route and then into the systemic circulation.

When vesicular transport in tanycytes is blocked, Tau efflux from CSF to blood is blunted, and Tau pathology intensifies.

In Alzheimer’s disease, where tanycytes exhibit fragmented processes and altered expression of vesicular transport genes, this bridge appears damaged.

Understanding and preserving this hidden link between brain and blood may be essential for limiting Tau accumulation and its harmful downstream effects.

References

Gonzalez-Ortiz F, Turton M, Kac PR, Smirnov D, Premi E, Ghidoni R, Benussi L, Cantoni V, Saraceno C, Rivolta J, Ashton NJ, Borroni B, Galasko D, Harrison P, Zetterberg H, Blennow K, Karikari T. Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration. Brain. 2023 Mar 1;146(3):1152–1165. doi: 10.1093/brain/awac407. Erratum in: Brain. 2023 Oct 3;146(10):e89-e90. doi: 10.1093/brain/awad208. PMID: 36572122; PMCID: PMC9976981.

Harada R, Lerdsirisuk P, Shimizu Y, Yokoyama Y, Du Y, Kudo K, Ezura M, Ishikawa Y, Iwata R, Shidahara M, Ishiki A, Kikuchi A, Hatano Y, Ishihara T, Onodera O, Iwasaki Y, Yoshida M, Taki Y, Arai H, Kudo Y, Yanai K, Furumoto S, Okamura N. Preclinical characterization of the tau PET tracer [18F]SNFT-1: comparison of tau PET tracers. J Nucl Med. 2023 Sep;64(9):1495–1501. doi:10.2967/jnumed.123.265593. Epub 2023 Jun 15. PMID: 37285275.

Petrozziello T, Amaral AC, Dujardin S, Farhan SMK, Chan J, Trombetta BA, Kivisäkk P, Mills AN, Bordt EA, Kim SE, Dooley PM, Commins C, Connors TR, Oakley DH, Ghosal A, Gomez-Isla T, Hyman BT, Arnold SE, Spires-Jones T, Cudkowicz ME, Berry JD, Sadri-Vakili G. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Brain Pathol. 2022 Mar;32(2):e13035. doi: 10.1111/bpa.13035. Epub 2021 Nov 14. PMID: 34779076; PMCID: PMC8877756.

Samelson AJ, Ariqat N, McKetney J, Rohanitazangi G, Parra Bravo C, Bose RS, Travaglini KJ, Lam VL, Goodness D, Ta T, Dixon G, Marzette E, Jin J, Tian R, Tse E, Abskharon R, Pan HS, Carroll EC, Lawrence RE, Gestwicki JE, Rexach JE, Eisenberg DS, Kanaan NM, Southworth DR, Gross JD, Gan L, Swaney DL, Kampmann M. CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis. Cell. 2026 Mar 5;189(5):1517–1534.e19. doi: 10.1016/j.cell.2025.12.038. Epub 2026 Jan 28. PMID: 41610849; PMCID: PMC12978015.

Sauvé F, Martinez-Gómez R, Mbouamboua Y, Ternier G, Nampoothiri S, Dupré E, Garcia L, Couralet M, Dewisme J, Lebouvier T, Danis C, Rasika S, Dhenain M, Kim YB, Ciofi P, Buée L, Landrieu I, Pasquier F, Lilamand M, Paquet C, Giacobini P, Barbry P, Maurage CA, Nogueiras R, Schwaninger M, Prevot V. Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology. Cell Press Blue. 2026 Apr 20;1(1):100003. doi: 10.1016/j.cpblue.2026.100003. PMID: 42180652; PMCID: PMC13197209.

Tangavelou K, Bondu V, Li M, Li W, Liao FF, Bhaskar K. The deubiquitinase OTULIN regulates tau expression and RNA metabolism in neurons. Genom Psychiatry. 2025 Nov 29;1(6):48–58. doi: 10.61373/gp025a.0116. Epub 2025 Nov 25. PMID: 41799830; PMCID: PMC12962826.

Tyagi M, Chadha R, de Hoog E, Sullivan KR, Walker AC, Northrop A, Fabian B, Fuxreiter M, Hyman BT, Shepherd JD. Arc mediates intercellular tau transmission via extracellular vesicles. bioRxiv [Preprint]. 2024 Oct 22:2024.10.22.619703. doi: 10.1101/2024.10.22.619703. PMID: 39484489; PMCID: PMC11526995.

To stay active and empowered with research-backed, evidence-based health and wellness content daily and learn its practical application in routine, don’t forget to follow my BioTuberOnline, Substack, Medium, LinkedIn, Patreon, and Blogger platforms.

As a health scientist, I would love to learn about your health and wellness experiences and insights into your encounters with ongoing or prior treatments/health support measures.

As we collaborate on this fascinating yet adventurous health and wellness journey, please share the next health topics/clinical research breakthroughs you would like me to bring to your desk.

Subscribe to my educational channel **BioTuberOnline** for more health and wellness updates, all backed by rigorous scientific evidence.

[embed]

Stay tuned & have a wonderful day!

Truly yours,

Dr. Khalid Rahman

Health Scientist | Scholarly Communicator | Licensed Integrative Medicine Practitioner | PhD (Clinical Research) | MSc (Bioinformatics) | MSc (Clinical Research & Regulatory Affairs) | Post Graduate Diploma in Computer Application | Bachelor of Unani Medicine & Surgery